Guo Chuangxing, Hou Xinjun, Dong Liming, Marakovits Joseph, Greasley Samantha, Dagostino Eleanor, Ferre RoseAnn, Johnson M Catherine, Humphries Paul S, Li Haitao, Paderes Genevieve D, Piraino Joseph, Kraynov Eugenia, Murray Brion W
Oncology Medicinal Chemistry, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA.
Oncology Medicinal Chemistry, Pfizer Worldwide Research & Development, San Diego, CA 92121, USA.
Bioorg Med Chem Lett. 2014 Sep 1;24(17):4187-91. doi: 10.1016/j.bmcl.2014.07.044. Epub 2014 Jul 22.
The design of potent Pin1 inhibitors has been challenging because its active site specifically recognizes a phospho-protein epitope. The de novo design of phosphate-based Pin1 inhibitors focusing on the phosphate recognition pocket and the successful replacement of the phosphate group with a carboxylate have been previously reported. The potency of the carboxylate series is now further improved through structure-based optimization of ligand-protein interactions in the proline binding site which exploits the H-bond interactions necessary for Pin1 catalytic function. Further optimization using a focused library approach led to the discovery of low nanomolar non-phosphate small molecular Pin1 inhibitors. Structural modifications designed to improve cell permeability resulted in Pin1 inhibitors with low micromolar anti-proliferative activities against cancer cells.
强效Pin1抑制剂的设计一直具有挑战性,因为其活性位点能特异性识别磷酸化蛋白表位。此前已有报道基于磷酸识别口袋从头设计基于磷酸盐的Pin1抑制剂,并成功用羧酸盐取代了磷酸基团。现在,通过对脯氨酸结合位点中配体 - 蛋白质相互作用进行基于结构的优化,进一步提高了羧酸盐系列的效力,该优化利用了Pin1催化功能所需的氢键相互作用。使用聚焦文库方法进行进一步优化,发现了低纳摩尔浓度的非磷酸盐小分子Pin1抑制剂。旨在提高细胞通透性的结构修饰产生了对癌细胞具有低微摩尔抗增殖活性的Pin1抑制剂。